BSE · 544738
Speciality Medicines Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹59 Cr with net profit ₹9 Cr — a 14.7% net margin, versus 10.61% the period before.
Shareholding
As of 2026-03-31
- Promoter43.43%
- Public56.33%
- FII0.24%
757 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.15× from low to high.
Risk flags
Derived from disclosed data
- Promoter holding fell 18.97 percentage points to 43.43% in the latest disclosure.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #1 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,77,444 Cr | 176.1 | 5.71 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,101 Cr | 214.6 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,990 Cr | 88.75 | 4.13 | 18.59% | 18.86% |
| Lupin Limited | ₹1,11,885 Cr | 19.67 | 4.98 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,077 Cr | 192.91 | 6.57 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,246 Cr | 88.01 | 18.16 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹95,344 Cr | 431.06 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,388 Cr | 100.3 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,837 Cr | 545.38 | 2.05 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,823 Cr | 286.92 | 4.91 | 16.66% | 15.65% |
| Speciality Medicines Limited(this company) | — | — | — | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashSpeciality Medicines Limited has a debt-to-equity ratio of 0.17. The company's 52-week high is Rs 381.2 and its 52-week low is Rs 121.1. As of March 31, 2026, promoter holding stands at 43.4281%, with public holding at 56.3329%. The company is currently under ESM Stage 1 surveillance.
Positives
- +Revenue increased by 111.66% from Rs 27.6572 Cr in Mar 2024 to Rs 58.5397 Cr in Mar 2025.
- +Net profit grew by 193.44% from Rs 2.9336 Cr in Mar 2024 to Rs 8.6082 Cr in Mar 2025.
- +Earnings per share (EPS) increased by 99.43% from Rs 7.07 in Mar 2024 to Rs 14.1 in Mar 2025.
- +The debt-to-equity ratio is 0.17, indicating a low level of debt.
- +Promoter pledging is 0%, indicating no shares are pledged.
Negatives
- −Promoter holding decreased from 62.3932% in Sep 2025 to 43.4281% in Mar 2026.
- −No market capitalization figures are available.
- −No quarterly financial results are disclosed.
- −The company is under ESM Stage 1 surveillance, which may indicate higher risk.
- −No information on book value, PE ratio, EPS, ROE, or ROCE is available for the latest period.
Financial Performance
Revenue increased to Rs 58.5397 Cr in Mar 2025 from Rs 27.6572 Cr in Mar 2024. Net profit also rose to Rs 8.6082 Cr in Mar 2025 from Rs 2.9336 Cr in Mar 2024. Earnings per share (EPS) grew to Rs 14.1 in Mar 2025 from Rs 7.07 in Mar 2024.
Balance Sheet
The company maintains a low debt-to-equity ratio of 0.17, indicating a limited reliance on borrowed capital. No other balance sheet figures are available in the provided data.
Ownership & Pledges
There are no promoter shares pledged, as indicated by a promoter pledge figure of 0%.
Regulatory & Surveillance
Speciality Medicines Limited is currently under ESM Stage 1 surveillance. This indicates that the company has been placed on the Enhanced Surveillance Measure framework.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Speciality Medicines Limitedshare price & fundamentals